Image via Wikipedia
Researchers funded by the National Institutes of Health have converted stem cells from the human endometrium into insulin-producing cells and transplanted them into mice to control the animals’ diabetes.
The endometrium, or uterine lining, is a source of adult stem cells. Normally, these cells generate uterine tissue each month as part of the menstrual cycle. Like other stem cells, however, they can divide to form other kinds of cells.
The study’s findings suggest the possibility that endometrial stem cells could be used to develop insulin-producing islet cells. These islet cells could then be used to advance the study
THE SWIRL of controversy that greeted President Obama’s executive order lifting the ban on federal funding of stem cell research in March didn’t make a significant return when the final rules were released over the summer. That’s because the National Institutes of Health successfully navigated a minefield of ethical and moral questions. To protect those regulations from politics and changes by another administration, Rep. Diana DeGette (D-Colo.) soon will introduce the Stem Cell Research Enhancement Act of 2009. The legislation would codify Mr. Obama’s executive order permitting federal funding of such research within guidelines established by the NIH and
Scientists at the UCSF-affiliated Gladstone Institutes and an international team of researchers have generated a human model of Huntington’s disease — directly from the skin cells of patients with the disease.
For years, scientists have studied Huntington’s disease primarily in post-mortem brain tissue or laboratory animals modified to mimic the disease. Today, in Cell Stem Cell, the international team shows how they developed a human model of Huntington’s disease, which causes a diverse range of neurological impairments. The new model should help scientists better understand the development of Huntington’s — and provide better ways to identify and screen potential therapeutics
Image via Wikipedia
Stem cell researchers have a lot of big dreams, and one is to someday regenerate damaged hearts. That is still many years away from becoming a commercial reality, if ever, but a few University of Washington scientists have formed a new company that hopes to make cells that can replace pacemakers, and someday rebuild damaged heart tissue that people are left with after heart attacks.
The company, Bellevue, WA-based Beat BioTherapeutics, is the brainchild of Chuck Murry and Michael Laflamme, a pair of UW stem cell researchers, and UW bioengineering professor Buddy Ratner. It has roots in about
A year after President Barack Obama issued a landmark executive order to remove eight years of limitations on U.S. federal funding of stem cell research, the WiCell Research Institute has expanded the number of cell lines available through its WISC Bank (Wisconsin International Stem Cell) to 33.
WiCell, host of the former National Stem Cell Bank (NSCB) for five years under a contract from the National Institutes of Health (NIH), has transitioned the distribution of all of the 20 human embryonic stem cell (hESC) lines formerly available through the NSCB to its own stem cell bank. The bank also continues